Mild Cognitive Impairment in Men Following Androgen Deprivation
Launched by IMPERIAL COLLEGE LONDON · Sep 20, 2012
Trial Information
Current as of June 24, 2025
Withdrawn
Keywords
ClinConnect Summary
Changes in cognitive function related to altered serum sex hormone levels are well-recognised but poorly understood. Mild cognitive impairment (MCI) with aging is thought in part to be related to reduction in serum androgen level and international studies are on-going to prevent age-related MCI using androgen replacement therapy. Reduction in cognitive function often leads to morbidity and reduction in quality of life. The commonest therapeutically induced reduction in sex hormone level in men is in the treatment of prostate cancer. As prostate cancer is androgen dependent for growth, andro...
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Male patients between the ages 50 to 90 years beginning ADT with LHRHa or PATCH participants randomised to either LHRHa or transdermal oestrogen for either newly diagnosed advanced prostate cancer or previously treated with radical radiotherapy or surgery and now having a rising prostate specific antigen will be included in the study.
- Exclusion Criteria:
- • Patients with a known history of dementia will be excluded as well as those patients who have received any prior hormone therapy for localised prostate cancer.
About Imperial College London
Imperial College London is a world-renowned research institution based in the United Kingdom, recognized for its commitment to advancing medical science and improving patient care through innovative research and clinical trials. With a strong emphasis on interdisciplinary collaboration, Imperial combines expertise across various fields, including medicine, engineering, and business, to drive breakthroughs in healthcare. The institution’s robust clinical trial programs are designed to evaluate new therapies and interventions, ensuring rigorous scientific standards and ethical practices while aiming to translate research findings into tangible benefits for patients and society.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
London, , United Kingdom
Patients applied
Trial Officials
Paul D Abel, ChM, FRCS
Study Chair
Imperial College London and Imperial College Healthcare NHS Trust
Syed IA Shah, MBBS, MPhil
Principal Investigator
Imperial College London and Imperial College Healthcare NHS Trust
Adam Waldman
Principal Investigator
Imperial College Healthcare NHS Trust
Basant K Puri
Principal Investigator
Imperial College Healthcare NHS Trust
Pat Price
Principal Investigator
Imperial College London
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials